Below is an extract from the above link. I know this link has been posted before, and some of its content, but the statement below says it all to me
In summary, routinely available peritoneal liquid biopsy specimens from GC patients provided a simple ex vivo platform for investigating the efficacy of the CF33-hNIS-antiPDL1 treatment.We show that: (1) CF33-hNIS-antiPDL1 effectively infects and kills human peritoneal GCPM cancer cells,(2) anti-PD-L1 scFv expressed by the virus-infected cancer cells blocks PD-L1 on cancer cells, and (3) CF33-hNIS-antiPDL1 decreases immune inhibitory factors and growth factors to create an anti-tumor immune microenvironment. These findings encourage the further development of CF33-hNIS-antiPDL1 into effective immunotherapeutic agents for the IP treatment of GCPM
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)